Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Glucose-dependent Insulinotropic Polypeptide (GIP)
Glucose-dependent Insulinotropic Polypeptide · 1 trial · 2 indications
Measured as number of events.
| Arm | Type | Description |
|---|---|---|
| Arm 1:Glucose dependent Insulinotropic Polypeptide(GIP)+Cagrilintide then Placebo GIP+Cagrilintide | EXPERIMENTAL | Participants will receive low dose of GIP and Cagrilintide escalated to medium dose of GIP and high dose of Cagrilintide in treatment period 1 followed by GIP Placebo along with escalating doses of Cagrilintide from low to high in treatment period 2. |
| Arm 2: Placebo GIP + Cagrilintide then GIP + Cagrilintide | EXPERIMENTAL | Participants will receive GIP placebo along with escalating doses of Cagrilintide from low to high in treatment period 1 followed by low dose of GIP and Cagrilintide escalated to medium dose of GIP and high dose of Cagrilintide in treatment period 2. |
| Arm 3: GIP + Cagrilintide then Placebo GIP + Cagrilintide | EXPERIMENTAL | Participants will receive high dose of GIP and low dose of Cagrilintide escalated to higher dose of GIP and high dose of Cagrilintide in treatment period 1 followed by GIP Placebo along with escalating doses of Cagrilintide from low to high in treatment period 2. |
| Arm 4: Placebo GIP + Cagrilintide then GIP + Cagrilintide | EXPERIMENTAL | Participants will receive GIP placebo along with escalating doses of Cagrilintide from low to high in treatment period 1 followed by medium dose of GIP and low dose of Cagrilintide escalated to higher dose of GIP and high dose of Cagrilintide in treatment period 2. |
| Name | Type | Description |
|---|---|---|
| Glucose-dependent Insulinotropic Polypeptide (GIP) | DRUG | Participants will receive GIP subcutaneously. |
| Cagrilintide | DRUG | Participants will receive Cagrilintide subcutaneously. |
| Placebo GIP | DRUG | Participants will receive placebo matched to GIP subcutaneously. |
Inclusion Criteria: * Female at birth. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 27.0 kilograms per square meter (kg/m\^2) and 39.9 kg/m\^2 (both inclusive) at screening. * Overweight should be due to excess adipose tissue, as ju...
Glucose-dependent Insulinotropic Polypeptide (GIP) is being developed for the treatment of overweight and obesity. It is an investigational small molecule being studied in a Phase 1 clinical trial in the United Kingdom. The drug is administered as a weekly injection and is being evaluated in people who are overweight or obese.
Glucose-dependent Insulinotropic Polypeptide is being developed by Novo Nordisk A/S, a pharmaceutical company traded on the stock exchange under the ticker symbol NVO. The company is conducting clinical research on this investigational drug for the treatment of overweight and obesity.
Glucose-dependent Insulinotropic Polypeptide is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 1 trial is recruiting participants in the United Kingdom.
Glucose-dependent Insulinotropic Polypeptide is being studied in one Phase 1 clinical trial with the identifier NCT07411560. This randomized, double-blind, controlled study is examining how weekly injections of GIP and amylin affect stomach-related side effects in people who are overweight or obese. The trial is recruiting female participants aged 18 years and older in the United Kingdom.
Yes, Glucose-dependent Insulinotropic Polypeptide is also known as GIP. This alternative name is used in clinical trial documentation and research contexts. The drug is being developed by Novo Nordisk A/S for the treatment of overweight and obesity, and is currently in Phase 1 clinical trials.